Tobacco-Related CarcinomaNCT07739706
A Novel Smartphone Application for Helping Teens Stop Vaping, QuitQuest Vaping R01
A study testing Smartphone Application-based Intervention, Survey Administration and Interview in people with Tobacco-Related Carcinoma, run by Fred Hutchinson Cancer Center at 1 site in United States.
Trial summary
This clinical trial compares a novel smartphone application (app) called QuitQuest to the National Cancer Institute's (NCI's) SmokefreeTeenQuitVaping (SFTQV) app in helping teens stop vaping. Read more about this study
- Who is it for?
- Ages 13 to 17 yearsHealthy volunteers can take part
- Conditions the study is for
- Tobacco-Related Carcinoma
- What is being tested?
- Smartphone Application-based Intervention, Survey Administration and Interview
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,072 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Dec 2026to 31 Mar 2031
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 17 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Age 13 to 17
- Used ENDS at least weekly in the past 30 days
- Wants to quit ENDS within the next 30 days
- If concurrently using any other nicotine or tobacco products, wants to quit using them within the next 30 days
- Interest in learning skills to quit ENDS
- Willing to be randomly assigned to either condition
Show all 15Show fewer
- Resides in the United States (US) for the next 12 months
- Has daily access to their own smartphone
- Ability to download a smartphone app
- Able to read in English
- Not using other ENDS cessation interventions
- Have not participated in our prior studies
- No household or family member participating
- Willingness to complete survey and biochemical assessments at 3, 6, and 12 months
- Providing phone number(s), email, and mailing address
Who cannot join
- Exclusion criteria are the reverse of the inclusion criteria
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109
Jonathan Bricker, PhD, 206-667-5074, jbricker@fredhutch.org
Jonathan Bricker, PhD
About this study
Official title: QuitQuest: Full Scale Randomized Trial of a Novel Smartphone Application to Help Teens Stop Vaping (QuitQuest Vaping R01)
This clinical trial compares a novel smartphone application (app) called QuitQuest to the National Cancer Institute's (NCI's) SmokefreeTeenQuitVaping (SFTQV) app in helping teens stop vaping. Despite recent declines, data shows that 8.5% of middle school (grades 6-8) and 18.1% of high school (grades 9-12) students in the United States (US) used electronic nicotine delivery systems (ENDS; variously known as vaping, electronic [e]-cigarettes, e-cigs, mods, and tank systems that contain nicotine). Use of any tobacco product during adolescence increases risk for lifelong nicotine addiction. ENDS use, in particular, leads to severe asthma attacks, e-cigarette or vaping product use-associated lung injury (EVALI), exposure to multiple lung irritants, including volatile organic compounds, and lasting harm to adolescent brain development. Despite evidence of potential long-term harms from ENDS, to date there have been limited evidence-based therapeutic options for ENDS cessation for adolescents and young adults. Traditional methods for delivering adolescent ENDS cessation interventions (e.g., quitlines and clinics) have limited reach. QuitQuest utilizes Acceptance and Commitment Therapy (ACT), a psychological intervention that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies, to increase psychological flexibility, reduce distress, and promote behavior change through mechanisms that include cultivating acceptance of internal experience and aligning behavior with personal values. The SFTQV program is based on the US Clinical Practice Guidelines, offering practical advice and support via an app delivery format. The QuitQuest app may work better than the SFTQV app in increasing vape quit rates among teens.
Read the detailed description
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I: Participants download and install the QuitQuest app for 12 months on study.
ARM II: Participants utilize the National Cancer Institute's (NCI's) SFTQV app for 12 months on study.
- Conditions
- Tobacco-Related Carcinoma
- Being tested
- Smartphone Application-based Intervention, Survey Administration, Interview
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Smartphone Application-based InterventionBehavioural
Also called Smartphone App-based Intervention, Smartphone Intervention, Smartphone-based Intervention
Use QuitQuest app
Smartphone Application-based InterventionBehavioural
Also called Smartphone App-based Intervention, Smartphone Intervention, Smartphone-based Intervention
Use SFTQV app
Survey AdministrationOther
Ancillary studies
InterviewOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Arm I (QuitQuest app) | Experimental | Participants download and install the QuitQuest app for 12 months on study. Receives: Behavioral: Smartphone Application-based Intervention; Other: Survey Administration; Other: Interview |
| Arm II (SFTQV app) | Active comparator | Participants utilize the NCI's SFTQV app for 12 months on study. Receives: Behavioral: Smartphone Application-based Intervention; Other: Survey Administration; Other: Interview |
What is being measured
The primary outcome is the main question the study is designed to answer.
Self-reported 30-day point prevalence abstinence (PPA) from electronic nicotine delivery systems (ENDS) use
Biochemical verification will be used to validate self-reported abstinence among participants who opt in at baseline and complete testing. In the primary intent-to-treat analysis, participants with missing 6-month self-reported outcome data will be classified as vaping. The primary missing=vaping outcome is based on self-reported 30-day ENDS use status, not on completion of biochemical verification. Participants who self-report abstinence but do not complete biochemical testing will not be automatically classified as vaping solely because biochemical verification is missing. The primary logistic regression model will adjust for the stratification factors used in randomization to appropriately account for study design, thereby improving the estimation of standard errors and increasing the validity of significance tests for the main treatment effect.
Measured: At 6 months post-randomization
Secondary outcomes (5)
Self-reported 30-day PPA from ENDS use
Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.
Measured: At 3 and 12 months post-randomization
Self-reported 24-hour PPA from ENDS use
Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.
Measured: At 3, 6, and 12 months post-randomization
Self-reported 7-day PPA from ENDS use
Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.
Measured: At 3, 6, and 12 months post-randomization
Self-reported 30-day PPA from ENDS use
Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.
Measured: At 3, 6, and 12 months post-randomization
Biochemical verification of self-reported abstinence among participants who opt in at baseline and complete testing
Measured: Up to 12 months post-randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2026
- Study start1 Dec 2026 (estimated)
- Primary completion31 Mar 2030 (estimated)
- Study completion31 Mar 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Tobacco-Related CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 1,072 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fred Hutchinson Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), Endeavor Health
- Responsible party
- Sponsor
- Investigators
- Jonathan Bricker, PhD, Principal investigator, Fred Hutch/University of Washington Cancer ConsortiumSean David, MD, Principal investigator, Endeavor Health Clinical Operations
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07739706
- Sponsor's protocol ID
- RG1126381
- Other IDs
- NCI-2026-04135, FHIRB0021244, R01CA301535
- Status last verified
- Jul 2026
- First submitted
- 28 Jul 2026
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The trial results data will be published in ClinicalTrials.gov at the time of study completion. The de-identified scientific data will be made available to other users no later than the time of publication of the primary outcomes, or at the end of the performance period, whichever comes first. The de-identified scientific data will be made available as public use data to the research community in openICPSR. Members of the research community using this data must register with ICPSR and agree to the Terms of Use, which include limiting data use to scientific research and requiring users agree not to share or redistribute any data downloads. No personally identifiable information (PII) or protected health information (PHI) data will be shared or available for secondary use. The de-identified data deposited in openICPSR will be available to the research community in perpetuity.